We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Vermillion Announces U.S. Patent Office Re-Issues Seldi Mass Spectrometry Patent

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Vermillion, Inc. has announced that the United States Patent and Trademark Office has issued a Reexamination Certificate of U.S. Patent No. 6,734,022, which is directed to a fundamental process of SELDI mass spectrometry.

As a result of the patent reissuance, Bio-Rad Laboratories is expected to pay Vermillion $2.0 million pursuant to the terms of the Asset Purchase Agreement entered into in connection with the sale of Vermillion's instrumentation business to Bio-Rad on November 13, 2006.

"We believe this patent further validates the innovation underlying SELDI technology and look forward to receiving Bio-Rad's payment," said Gail S. Page, President and Chief Executive Officer of Vermillion. "We continue to make excellent progress translating the SELDI-enabled biomarker discoveries into novel, high-value molecular diagnostic tests."